NumFin

Spectrum Pharmaceuticals, Inc.

Symbol: SPPI

NASDAQ

1.03

USD

Market price today

  • -5.7473

    P/E Ratio

  • -0.0806

    PEG Ratio

  • 211.40M

    MRK Cap

  • 0.00%

    DIV Yield

Spectrum Pharmaceuticals, Inc. (SPPI) Financial Statements

Download
AnnualQuarterly
LinearLog
On the chart you can see the default numbers in dynamics for Spectrum Pharmaceuticals, Inc. (SPPI). Companys revenue shows the average of 57.094 M which is 1525.225 % gowth. The average gross profit for the whole period is 45.522 M which is 1.177 %. The average gross profit ratio is 61038.367 %. The net income growth for the company last year performance is -0.507 % which equals -0.331 % % on average for the whole company history.,

AnnualQuarterly
10Y20Y30Y40Y

Balance Sheet

Diving into the fiscal trajectory of Spectrum Pharmaceuticals, Inc., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of -0.074. In the realm of current assets, SPPI clocks in at 101.011 in the reporting currency. A significant portion of these assets, precisely 75.096, is held in cash and short-term investments. This segment shows a change of -0.254% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 5.967, if any, in the reporting currency. This indicates a difference of 0.000% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 28.666 in the reporting currency. This figure signifies a year_over_year change of 21.954%. Shareholder value, as depicted by the total shareholder equity, is valued at 27.888 in the reporting currency. The year over year change in this aspect is -0.414%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 13.613, with an inventory valuation of 9.23, and goodwill valued at 0, if any. The total intangible assets, if present, are valued at 0.

common:word.in-mln

USD
Growth
TTM202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996

balance-sheet.row.cash-and-short-term-investments

299.4475.1100.6180
223.9
204
227.6
158.5
140
133.2
159.8
143
161.3
95.7
113.3
78.1
55.7
50.7
63.7
39.2
26.4
1.6
7.2
11.5
9.7
1.1
6.1
10

balance-sheet.row.short-term-investments

124.9434.712.1134
159.5
46.5
0.2
0.2
0.2
3.3
3.5
3.3
40.1
42.1
31
68.2
54.5
50.2
34.9
36
1.8
0.1
6.4
5.3
3
0
0
0

balance-sheet.row.net-receivables

48.4513.612.5
10
33.6
34.4
45.5
43
76.2
57
92.2
51.7
21.1
8.7
5
0.2
1.1
0.3
0.2
0
0.2
0.5
0.4
0.1
0.1
0.2
0.2

balance-sheet.row.inventory

31.469.200
0
3.5
5.7
8.7
4.2
9.2
13.5
14.5
10.8
4.2
3.2
1.8
0
0
0.1
0.2
0.3
0.2
0
0
0
0
0
0

balance-sheet.row.other-current-assets

13.63.12.34.2
10.1
0.6
1.9
3.9
4.2
3.8
4.9
15.2
2.1
0.9
113.3
0.7
0
0
0.4
0.4
0.1
0.6
0
0.4
0.1
2.2
3.2
5.9

balance-sheet.row.total-current-assets

392.95101104186.6
244
250.7
277.7
216.7
191.3
222.5
235.2
264.9
225.8
121.9
126.3
85.6
56.6
52.3
64.4
40
26.8
2.6
8
12.3
10
3.4
9.5
16.1

balance-sheet.row.property-plant-equipment-net

8.562.235.8
15.4
0.4
0.6
0.4
0.9
1.4
1.5
2.5
2.7
3.2
1.9
1.8
0.7
0.6
0.6
0.7
0.6
0.8
4.7
3.4
3.2
3.3
3.5
0.1

balance-sheet.row.goodwill

0000
0
18.1
18.2
17.9
18
18.2
18.5
29
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

0000
0
111.6
137.2
164.2
190.3
230.1
231.4
202.3
41.7
0
33.3
37
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

0000
0
129.7
155.3
182.1
208.3
248.3
249.9
231.3
41.7
29.6
33.3
37
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-investments

5.97600
0
0
37.5
11.5
6.7
8.5
3.6
0
9.3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

0000
0
0
-37.5
-11.5
-6.7
-8.5
-3.6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

1.89-5.84.64.3
4
10.2
16.3
18
14
9.4
9
7.6
1.4
9
11.6
0.3
0.2
0.2
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.2
1.8

balance-sheet.row.total-non-current-assets

16.422.37.610.2
19.4
140.2
209.7
212.1
229.9
267.6
264
241.4
55
41.8
46.9
39.1
0.9
0.8
0.7
0.8
0.6
0.9
4.8
3.5
3.2
3.4
3.7
1.9

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

409.37103.3111.5196.8
263.4
390.9
487.4
428.8
421.2
490
499.2
506.3
280.8
163.6
173.1
124.7
57.5
53.1
65.1
40.8
27.4
3.5
12.8
15.8
13.2
6.8
13.2
18

balance-sheet.row.account-payables

148.6238.141.343.8
54.3
69.5
58.1
52.5
56.5
85
73.4
34.4
9.8
0
0
5.6
1.6
2.1
1.2
1.6
1.5
2
4.2
3.7
3.6
1.3
1
0.3

balance-sheet.row.short-term-debt

30.81.31.5
1.7
9.9
38.2
9
8.2
8.4
6.9
0
42
0
0
7.5
0
0
0
0
0.1
0.3
0.8
1.1
1
0.4
1.5
0.6

balance-sheet.row.tax-payables

2.72.700
0
0
0
0
0
0
0
0.5
1.4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

85.9928.700
2.4
0
0
97
101.5
96.3
91.5
75
0.3
0
0.1
0.1
0
0
0
0
0
0.2
0.5
0.5
0.6
1.1
0
0

Deferred Revenue Non Current

0000
0
0
0.3
0.3
0.4
0
1.4
2.9
14
25.5
24.9
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

20.613.810.77.8
6
2.3
9.5
9.8
13.7
14.5
16.4
81.7
56.4
51
31.2
12.8
6.2
4.1
2.6
1.1
1.4
0.2
0.2
0.3
0.1
0.7
0
0.5

balance-sheet.row.total-non-current-liabilities

113.1532.810.89.4
11.1
21.1
26.4
127.2
132
126
127.6
93
14.3
25.8
25.3
42.8
1
1
0.2
0.2
0
0.3
0.8
0.6
0.7
1.1
0.2
0

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

30.81.31.5
4.1
0
0
0
0
0
0
0
0.3
0
0.1
0.1
0
0
0
0
0
0.2
0.5
0
0
0
0
0

balance-sheet.row.total-liab

285.3875.56462.6
73
107.6
136.1
192.7
208.4
235.5
217.5
221.4
92.9
89.2
64.8
70.9
8.8
7.3
4.1
2.8
3.1
2.8
6
5.7
5.5
3.5
2.7
1.4

balance-sheet.row.preferred-stock

0000
0
0
0
0
0.1
0.1
0.1
0.1
0.1
0.2
0.4
0.4
1
1.3
2.5
2.5
9.4
0
0
0
0
0
0
0

balance-sheet.row.common-stock

0.80.20.20.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0
0
0
0
0
0
0
0
0
100.6
58.1
0
0
0

balance-sheet.row.retained-earnings

-4442.41-1119.3-1043.9-885.3
-724.4
-599.9
-502.1
-402.6
-334.1
-283.3
-237.6
-179.3
-261.9
-310.4
-261.6
-257.2
-241.8
-207.7
-184.4
-165.8
-153.5
-143.1
-125.5
-96.8
-50.4
-24.3
-12.7
-6.5

balance-sheet.row.accumulated-other-comprehensive-income-loss

-11.77-2.9-3-1.8
-3.5
-3.7
16
-1.6
-5.3
-0.8
0.9
0.3
-0.2
-0.1
-0.1
-0.1
0.5
0.4
-0.8
-0.1
-0.2
-0.1
-2.4
-1
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

4577.361149.91094.41021.2
918.2
886.7
837.3
640.2
1104.2
1077.1
1036.3
927.4
899.7
769.5
739
593.1
577.9
503.8
487.3
402.4
337.2
143.8
134.7
0
0
27.6
23.2
23.1

balance-sheet.row.total-stockholders-equity

123.9927.947.6134.2
190.4
283.3
351.3
236
212.9
254.6
281.6
284.8
187.9
74.5
108.3
39.6
48.7
45.8
61
37.9
24.3
0.7
6.8
2.8
7.7
3.3
10.5
16.6

balance-sheet.row.total-liabilities-and-stockholders-equity

409.37103.3111.5196.8
263.4
390.9
487.4
428.8
421.2
490
499.2
506.3
280.8
163.6
173.1
124.7
57.5
53.1
65.1
40.8
27.4
3.5
12.8
15.8
13.2
6.8
13.2
18

balance-sheet.row.minority-interest

0000
0
0
0
0
0
0
0
0
0
0
0
14.3
0
0
0
0
0
0
0
7.3
0
0
0
0

balance-sheet.row.total-equity

123.9927.947.6134.2
190.4
283.3
351.3
236
212.9
254.6
281.6
284.8
187.9
74.5
108.3
53.9
48.7
45.8
61
37.9
24.3
0.7
6.8
10.1
7.7
3.3
10.5
16.6

balance-sheet.row.total-liabilities-and-total-equity

409.37---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

124.9434.712.1134
159.5
46.5
37.8
11.8
6.9
11.8
7.1
3.3
49.3
42.1
31
68.2
54.5
50.2
34.9
36
1.8
0.1
6.4
5.3
3
0
0
0

balance-sheet.row.total-debt

88.2229.41.31.5
4.1
0
38.2
97
101.5
96.3
91.5
75
0.3
0
0.1
7.6
0
0
0
0
0.1
0.5
1.3
1.6
1.7
1.5
1.5
0.6

balance-sheet.row.net-debt

-86.29-10.9-87.3-44.5
-60.4
-157.5
-189.1
-61.2
-38.2
-33.6
-64.8
-64.7
-120.9
-53.5
-82.3
-2.3
-1.1
-0.5
-28.8
-3.2
-24.4
-1
0.5
-4.5
-5.1
0.4
-4.6
-9.4

Cash Flow Statement

The financial landscape of Spectrum Pharmaceuticals, Inc. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of 0.187. The company recently extended its share capital by issuing 46.56, marking a difference of 23.030 compared to the previous year. The company's investing activities resulted in net cash usage, amounting to -26718000.000 in the reporting currency. This is a shift of -1.246 from the previous year. In the same period, the company recorded 0.25, 2.17, and 0, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated 0 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 29.03, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996

cash-flows.row.net-income

-64.97-75.4-158.6-160.9
-112.7
-120
-91.2
-68.5
-50.8
-45.7
-62.1
94.5
0
-48.8
-19
-15.5
-34
-23.3
-18.6
-12.3
-10.4
-17.6
-27.8
-46.4
-26
-11.6
-6.2
-1

cash-flows.row.depreciation-and-amortization

0.220.20.30.3
3.3
28.4
28
26.5
31.9
25.4
22.1
10.2
5.7
4.5
4.2
0.6
0.3
0.2
0.7
0.4
0.3
1.3
2.3
1.1
0.5
0.5
0.2
0

cash-flows.row.deferred-income-tax

0014.74
-1.7
0
-14.9
-2.3
7
5.9
2.7
-34.6
0
-12.3
-10.3
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

7.268.519.817.8
21.8
17.5
15.1
12.4
12.1
11.8
12.4
14.9
22.2
8.3
7.4
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

-33.75-35.22.6-12.5
-21.9
21.9
13.4
-17.8
1.3
-13.2
40.8
-5.1
-25.9
25
7.2
-2.2
2.2
2.3
1.3
-0.6
1.2
-2.7
0.2
-0.3
2.8
0.3
-0.1
-0.3

cash-flows.row.account-receivables

-32.76-130.10
29.4
2.8
7.7
-9.5
40.2
-21.7
42.6
-33.5
-30.9
-12.8
1.1
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

-3.49-9.200
-2
3.4
4.3
-5.8
1.9
4.3
1.6
-0.7
-7.8
-1.1
-1.4
-1.8
0
0
0.2
-0.2
0
0
0
0
0
0
0
0

cash-flows.row.account-payables

13.73-3.7-3.5-22.1
-35.8
11.4
5.5
-4
-28.3
5.3
-23.9
24.8
13.5
21.4
7.1
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

6.94-9.36.19.5
-13.5
4.3
-4.2
1.5
-12.5
-1.1
20.6
4.3
12.8
38.8
7.5
-0.4
2.2
2.3
1.2
-0.4
0
-2.7
0
0
0
0
0
0

cash-flows.row.other-non-cash-items

3.14.91.629.7
-23.5
-10.2
10.8
9.3
12.2
18.2
-15.3
-7.9
41.3
-11.5
-17.5
9.1
6.2
7.3
0.6
0.6
2.6
3.7
0.5
2.2
2.9
0.4
0.2
0.1

cash-flows.row.net-cash-provided-by-operating-activities

-88.13000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-0.34-0.3-0.2-5.5
-9
-2.8
-0.5
-0.1
-0.2
-0.9
-3.2
-25.7
-0.5
-1.6
-0.7
-1.5
-0.3
-0.3
-0.1
-0.2
0
-0.1
-1.4
-0.8
-0.4
-0.2
-3.6
-0.1

cash-flows.row.acquisitions-net

-0.25-2.26-4
158.6
0
0
0
0
0
-11.2
-133.3
0
0
-30.9
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.purchases-of-investments

-34.15-34.6-16.9-89.4
-200.2
0
-0.6
-0.6
0
0
0
-28.1
-17.2
-40.6
0
-23.3
-30
-14.9
-59.2
-44.5
-1.7
0
-1
-2.4
-1.2
0
0
-7.4

cash-flows.row.sales-maturities-of-investments

38.678.1125.8113
82.5
4.1
0
0
3.1
4.1
0
72.5
18.4
32.4
25.8
0
25.7
0
60.1
10.3
0
6.2
0
0
0
0.3
5.3
0

cash-flows.row.other-investing-activites

0.252.2-64
0.1
0
0
0
0
-25
-3
-50.9
0
0
0
0
0
0
0
0
0
0.8
-0.1
0
-0.1
0
0.1
-0.1

cash-flows.row.net-cash-used-for-investing-activites

4.18-26.7108.718.1
32
1.4
-1.1
-0.7
2.8
-21.8
-14.3
-114.7
0.7
-9.8
-5.8
-24.8
-4.6
-15.2
0.8
-34.4
-1.7
6.9
-2.4
-3.2
-1.7
0.1
1.8
-7.6

cash-flows.row.debt-repayment

0000
0
0
-27.5
-9
0
0
-175
-50
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-issued

28.3646.652.684.6
1.8
1.1
128.3
73.9
0
0
16.7
131.5
30.6
3.6
97.3
0
30.6
0.5
41.2
25
31.4
9.9
28.3
36.6
27.8
4.2
0
18.8

cash-flows.row.common-stock-repurchased

0000
0
0
-4.3
-1.4
-0.6
-1.7
-3.2
-10.5
-2.9
0
0
0
0
0
-0.4
0
0
-0.1
-5
0
-0.1
0
0
0

cash-flows.row.dividends-paid

0000
0
0
-6.5
0
0
0
-207.4
-9
0
0
0
0
0
0
0
0
0
0
-0.8
0
0
0
0
0

cash-flows.row.other-financing-activites

29.34290.70.7
7.8
-9.6
12.3
-3.8
2.1
2.5
196.7
130.5
-4.1
0
-1.3
41.5
0
0
0
-0.1
-0.3
-0.7
-0.7
9.3
-0.5
1.1
0
0

cash-flows.row.net-cash-used-provided-by-financing-activities

57.775.653.385.2
9.6
-8.5
108.7
59.6
1.5
0.8
35.3
61
23.6
3.6
95.9
41.5
30.6
0.4
40.7
24.9
31
9.1
21.9
46
27.2
5.3
0.2
18.8

cash-flows.row.effect-of-forex-changes-on-cash

-0.06-0.10-0.1
-0.1
-0.4
0.3
0
-1.3
-1.7
-2.2
0.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

-26.31-48.242.5-18.4
-93.1
-69.8
69.1
18.5
9.8
-26.4
16.6
18.5
67.6
-28.8
72.5
8.7
0.6
-28.2
25.5
-21.3
23.1
0.8
-5.4
-0.6
5.6
-5
-3.9
10

cash-flows.row.cash-at-end-of-period

174.5140.488.546
64.4
157.5
227.3
158.2
139.7
129.9
156.3
139.7
121.2
53.6
82.3
9.9
1.1
0.5
28.8
3.2
24.6
1.5
0.7
6.2
6.7
1.1
6.1
10

cash-flows.row.cash-at-beginning-of-period

200.8188.54664.4
157.5
227.3
158.2
139.7
129.9
156.3
139.7
121.2
53.6
82.3
9.9
1.1
0.5
28.8
3.2
24.6
1.5
0.7
6.2
6.7
1.1
6.1
10
0

cash-flows.row.operating-cash-flow

-88.13-97-119.5-121.6
-134.6
-62.4
-38.9
-40.5
6.7
-3.6
-2.1
72
43.3
-22.5
-17.6
-8
-25.4
-13.5
-16
-11.8
-6.2
-15.3
-24.8
-43.4
-19.8
-10.4
-5.9
-1.2

cash-flows.row.capital-expenditure

-0.34-0.3-0.2-5.5
-9
-2.8
-0.5
-0.1
-0.2
-0.9
-3.2
-25.7
-0.5
-1.6
-0.7
-1.5
-0.3
-0.3
-0.1
-0.2
0
-0.1
-1.4
-0.8
-0.4
-0.2
-3.6
-0.1

cash-flows.row.free-cash-flow

-88.47-97.3-119.7-127.2
-143.6
-65.2
-39.3
-40.5
6.5
-4.6
-5.2
46.2
42.8
-24.1
-18.3
-9.5
-25.8
-13.8
-16.2
-12
-6.2
-15.4
-26.2
-44.2
-20.3
-10.6
-9.5
-1.3

Income Statement Row

Spectrum Pharmaceuticals, Inc.'s revenue saw a change of 0.000% compared with the previous period. The gross profit of SPPI is reported to be 8.32. The company's operating expenses are 81.02, showing a change of -45.147% from the last year. The expenses for depreciation and amortization are 0.25, which is a -16.255% change from the last accounting period. Operating expenses are reported to be 81.02, which shows a -45.147% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a 0.508% year-over-year growth. The operating income is -72.7, which shows a -0.508% change when compared to the previous year. The change in the net income is -0.507%. The net income for the last year was -78.1.

common:word.in-mln

USD
Growth
TTM202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996

income-statement-row.row.total-revenue

25.7710.100
22.6
109.3
128.4
146.4
162.6
186.8
155.9
267.7
193
74.1
38
28.7
7.7
5.7
0.6
0.3
1
2.4
0
0
0
0.1
0.1
0.1

income-statement-row.row.cost-of-revenue

2.91.800
12
26.8
47.2
35.8
27.7
27
28.6
46.6
33.8
17.4
8.1
1.2
0
0.1
0.4
0.1
0
0
0
-1.1
-0.5
-0.5
-0.2
0

income-statement-row.row.gross-profit

22.878.300
10.6
82.6
81.1
110.6
134.9
159.8
127.3
221.1
159.1
56.7
29.9
27.5
7.7
5.6
0.2
0.1
1
2.4
0
1.1
0.5
0.6
0.3
0.1

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1.1
0.5
0
0
0

income-statement-row.row.research-development

43.44---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

-3.75-5.3-10.9-2.9
-8.9
9.6
0.4
0.9
-1.2
-4.4
-0.7
-0.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.operating-expenses

86.3881147.7169.7
140.7
213.8
177.8
172.2
175.6
191.4
166.1
141.3
104
109.6
58.4
42
44.9
31.5
20.1
12.9
11.3
16.8
28.2
45
24
12.1
7
1.3

income-statement-row.row.cost-and-expenses

89.2382.8147.7169.7
140.7
240.5
225
208.1
203.3
218.4
194.6
187.9
137.8
127
66.5
43.2
44.9
31.6
20.5
13.1
11.3
16.8
28.2
43.9
23.5
11.6
6.8
1.3

income-statement-row.row.interest-income

1.4210.21.3
5
0
0
0
0
0
0
0
0
0
0
0
0
2.6
0
0
0.1
0
0
0.8
0
0
0
0

income-statement-row.row.interest-expense

2.09100
-5
0.3
6.8
9.4
9.1
8.6
2.2
0
0
0
0
0
0
0
0
0
0
0
0
1.9
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

-4.17-5.4-10.7-1.6
-0.6
11.5
-4.6
0.2
-0.6
-3.4
2.1
-0.8
-2.9
4
0.7
-3.5
3.1
0.6
1.3
0
-0.2
-3.2
-0.2
0
-2.2
0.2
0.7
0.3

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

-3.75-5.3-10.9-2.9
-8.9
9.6
0.4
0.9
-1.2
-4.4
-0.7
-0.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.total-operating-expenses

-4.17-5.4-10.7-1.6
-0.6
11.5
-4.6
0.2
-0.6
-3.4
2.1
-0.8
-2.9
4
0.7
-3.5
3.1
0.6
1.3
0
-0.2
-3.2
-0.2
0
-2.2
0.2
0.7
0.3

income-statement-row.row.interest-expense

2.09100
-5
0.3
6.8
9.4
9.1
8.6
2.2
0
0
0
0
0
0
0
0
0
0
0
0
1.9
0
0
0
0

income-statement-row.row.depreciation-and-amortization

1.75-4.40.30.3
3.3
28.1
27.6
25.9
38.3
24.3
20.1
6.7
5.7
4.5
3.7
0.6
0.3
0.2
0.7
0.4
0.3
1.3
2.3
1.1
0.5
0.5
0.2
-0.3

income-statement-row.row.ebitda-caps

-61.88---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

-63.51-72.7-147.7-169.7
-144
-131.2
-96.7
-61.6
-40.7
-31.6
-38.8
79.8
55.1
-52.9
-28.5
-19.2
-37.2
-25.9
-19.9
-12.8
-10.5
-17.5
-28.1
-43.9
-23.5
-11.5
-6.7
-1.2

income-statement-row.row.income-before-tax

-67.68-78.1-158.4-171.3
-144.6
-120
-108
-70.8
-50.4
-43.5
-36.6
79
52.2
-48.9
-19.8
-22.7
-34.1
-25.3
-18.6
-12.8
-10.6
-20.7
-28.4
-43.9
-25.7
-11.3
-6
-0.9

income-statement-row.row.income-tax-expense

-2.6200-0.1
-9.2
0
-16.8
-2.3
0.4
2.2
25.5
-15.6
3.7
0
-0.4
1
-3.2
-2.6
-1.3
-0.5
0.1
3.2
-0.3
2.6
2.5
0.1
-0.5
0.1

income-statement-row.row.net-income

-65.06-78.1-158.4-171.3
-135.4
-120
-91.2
-68.5
-50.8
-45.7
-62.1
94.5
48.5
-48.8
-19
-15.5
-34
-23.3
-18.6
-12.3
-10.4
-17.6
-27.8
-46.4
-26
-11.6
-6.2
-1
Similar Stocks
You may also be interested in:
SRNE
Sorrento Therapeutics, Inc..
0.016 USD
NASDAQ
MRVI
Maravai LifeSciences Holdings, Inc..
9.01 USD
NASDAQ
CMRA
Comera Life Sciences Holdings, Inc..
0.0212 USD
NASDAQ
GUBRA.CO
Gubra A/S.
309 DKK
CPH
T5O.DE
CytoTools AG.
0.468 EUR
XETRA
6826.HK
Shanghai Haohai Biological Technology Co., Ltd..
42.4 HKD
HKSE
PPBT
Purple Biotech Ltd..
0.67 USD
NASDAQ

Frequently Asked Question

What is Spectrum Pharmaceuticals, Inc. (SPPI) total assets?

Spectrum Pharmaceuticals, Inc. (SPPI) total assets is 103338000.000.

What is enterprise annual revenue?

The annual revenue is 25729000.000.

What is firm profit margin?

Firm profit margin is 0.889.

What is company free cash flow?

The free cash flow is -0.322.

What is enterprise net profit margin?

The net profit margin is -1.400.

What is firm total revenue?

The total revenue is -1.481.

What is Spectrum Pharmaceuticals, Inc. (SPPI) net profit (net income)?

The net profit (net income) is -78104000.000.

What is firm total debt?

The total debt is 29427000.000.

What is operating expences number?

The operating expences are 81019000.000.

What is company cash figure?

Enretprise cash is 52373000.000.